Company news

Adial Pharmaceuticals, Inc news in 2026

Adial Pharmaceuticals, Inc's news releases, calls and decks from 2026, newest first.

View company

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

October 28, 2026

Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer

October 26, 2026

Amendment to Quarterly Report (Form 10-Q/A)

October 21, 2026

Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis

October 16, 2026

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

September 30, 2026

Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

August 25, 2026

Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing

June 16, 2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

June 11, 2026

Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update

May 11, 2026

Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045

April 29, 2026

Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program

April 27, 2026

Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial

April 22, 2026

Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans

March 24, 2026

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

March 5, 2026

Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement

March 3, 2026

Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement

February 24, 2026

Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One

February 23, 2026

Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 17, 2026

Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04

February 4, 2026

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement

February 3, 2026

Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045

January 14, 2026

Decks in 2026